$1.6 billion liquid biopsy player Grail files IPO, revealing 2021 commercial plans and a Midas-sized $65M pay package for Hans Bishop
The hunt for the Grail just got a lot easier. In fact, in a few weeks you’ll likely be able to pick up a portion of it on Robin Hood, no coconut horses required.
Grail, the monstrously backed liquid biopsy biotech, has filed for an IPO. No pricing details have been disclosed, but if history is any indicator, the company will have a chance to cap 6 months of booming pandemic-era offerings the way the billion-dollar Dark Knight films would cap the summer blockbuster in their heyday. CEO Hans Bishop has penciled in $100 million for the raise, but that figure has become a standard placeholder until biotechs can gauge exactly how much they can raise.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
